Impact of metabolic syndrome on oncologic outcome after radical gastrectomy for gastric cancer

Eun Hye Kim, Hyuk Lee, Hyunsoo Chung, Jun Chul Park, Sung Kwan Shin, SangKil Lee, WooJin Hyung, Yongchan Lee, Sung Hoon Noh

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Few studies have reported the relationship between MS and the prognosis of gastric cancer. Methods: Data were collected from 505 patients who underwent radical gastrectomy for gastric cancer between January 2006 and December 2007. After exclusion, remaining 204 patients were divided into two groups based on the presence of MS. Results: No significant differences were observed in tumor stage and grade between the MS (n=60) and non-MS (n=144) groups. The median follow-up periods were 53.2. ±. 23.5 and 54.7. ±. 22.1 months in for the MS and non-MS groups, respectively (P=0.677). Seventeen (28.3%) and 21 (14.6%) patients showed tumor recurrence in the MS and non-MS groups, respectively (P=0.022). In addition, disease-free survival of patients in the MS group was less than in non-MS group (P=0.036). The Cox regression hazard model demonstrated that advanced tumor stage (stage III or IV, HR=17.8, 95% CI=5.3 to 59.4) and presence of MS (HR=2.8, 95% CI=1.3 to 5.8) were independent risk factors for recurrence. Conclusion: MS may be an important prognostic factor for gastric cancer. Control of MS could improve the therapeutic efficacy of gastric cancer.

Original languageEnglish
Pages (from-to)372-378
Number of pages7
JournalClinics and Research in Hepatology and Gastroenterology
Volume38
Issue number3
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Gastrectomy
Stomach Neoplasms
Recurrence
Neoplasms
Proportional Hazards Models
Disease-Free Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Kim, Eun Hye ; Lee, Hyuk ; Chung, Hyunsoo ; Park, Jun Chul ; Shin, Sung Kwan ; Lee, SangKil ; Hyung, WooJin ; Lee, Yongchan ; Noh, Sung Hoon. / Impact of metabolic syndrome on oncologic outcome after radical gastrectomy for gastric cancer. In: Clinics and Research in Hepatology and Gastroenterology. 2014 ; Vol. 38, No. 3. pp. 372-378.
@article{5ef8aadee5e246eb8fb8d83fb05fe405,
title = "Impact of metabolic syndrome on oncologic outcome after radical gastrectomy for gastric cancer",
abstract = "Background: Few studies have reported the relationship between MS and the prognosis of gastric cancer. Methods: Data were collected from 505 patients who underwent radical gastrectomy for gastric cancer between January 2006 and December 2007. After exclusion, remaining 204 patients were divided into two groups based on the presence of MS. Results: No significant differences were observed in tumor stage and grade between the MS (n=60) and non-MS (n=144) groups. The median follow-up periods were 53.2. ±. 23.5 and 54.7. ±. 22.1 months in for the MS and non-MS groups, respectively (P=0.677). Seventeen (28.3{\%}) and 21 (14.6{\%}) patients showed tumor recurrence in the MS and non-MS groups, respectively (P=0.022). In addition, disease-free survival of patients in the MS group was less than in non-MS group (P=0.036). The Cox regression hazard model demonstrated that advanced tumor stage (stage III or IV, HR=17.8, 95{\%} CI=5.3 to 59.4) and presence of MS (HR=2.8, 95{\%} CI=1.3 to 5.8) were independent risk factors for recurrence. Conclusion: MS may be an important prognostic factor for gastric cancer. Control of MS could improve the therapeutic efficacy of gastric cancer.",
author = "Kim, {Eun Hye} and Hyuk Lee and Hyunsoo Chung and Park, {Jun Chul} and Shin, {Sung Kwan} and SangKil Lee and WooJin Hyung and Yongchan Lee and Noh, {Sung Hoon}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.clinre.2013.11.009",
language = "English",
volume = "38",
pages = "372--378",
journal = "Clinics and Research in Hepatology and Gastroenterology",
issn = "2210-7401",
publisher = "Elsevier Masson",
number = "3",

}

Impact of metabolic syndrome on oncologic outcome after radical gastrectomy for gastric cancer. / Kim, Eun Hye; Lee, Hyuk; Chung, Hyunsoo; Park, Jun Chul; Shin, Sung Kwan; Lee, SangKil; Hyung, WooJin; Lee, Yongchan; Noh, Sung Hoon.

In: Clinics and Research in Hepatology and Gastroenterology, Vol. 38, No. 3, 01.01.2014, p. 372-378.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of metabolic syndrome on oncologic outcome after radical gastrectomy for gastric cancer

AU - Kim, Eun Hye

AU - Lee, Hyuk

AU - Chung, Hyunsoo

AU - Park, Jun Chul

AU - Shin, Sung Kwan

AU - Lee, SangKil

AU - Hyung, WooJin

AU - Lee, Yongchan

AU - Noh, Sung Hoon

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Few studies have reported the relationship between MS and the prognosis of gastric cancer. Methods: Data were collected from 505 patients who underwent radical gastrectomy for gastric cancer between January 2006 and December 2007. After exclusion, remaining 204 patients were divided into two groups based on the presence of MS. Results: No significant differences were observed in tumor stage and grade between the MS (n=60) and non-MS (n=144) groups. The median follow-up periods were 53.2. ±. 23.5 and 54.7. ±. 22.1 months in for the MS and non-MS groups, respectively (P=0.677). Seventeen (28.3%) and 21 (14.6%) patients showed tumor recurrence in the MS and non-MS groups, respectively (P=0.022). In addition, disease-free survival of patients in the MS group was less than in non-MS group (P=0.036). The Cox regression hazard model demonstrated that advanced tumor stage (stage III or IV, HR=17.8, 95% CI=5.3 to 59.4) and presence of MS (HR=2.8, 95% CI=1.3 to 5.8) were independent risk factors for recurrence. Conclusion: MS may be an important prognostic factor for gastric cancer. Control of MS could improve the therapeutic efficacy of gastric cancer.

AB - Background: Few studies have reported the relationship between MS and the prognosis of gastric cancer. Methods: Data were collected from 505 patients who underwent radical gastrectomy for gastric cancer between January 2006 and December 2007. After exclusion, remaining 204 patients were divided into two groups based on the presence of MS. Results: No significant differences were observed in tumor stage and grade between the MS (n=60) and non-MS (n=144) groups. The median follow-up periods were 53.2. ±. 23.5 and 54.7. ±. 22.1 months in for the MS and non-MS groups, respectively (P=0.677). Seventeen (28.3%) and 21 (14.6%) patients showed tumor recurrence in the MS and non-MS groups, respectively (P=0.022). In addition, disease-free survival of patients in the MS group was less than in non-MS group (P=0.036). The Cox regression hazard model demonstrated that advanced tumor stage (stage III or IV, HR=17.8, 95% CI=5.3 to 59.4) and presence of MS (HR=2.8, 95% CI=1.3 to 5.8) were independent risk factors for recurrence. Conclusion: MS may be an important prognostic factor for gastric cancer. Control of MS could improve the therapeutic efficacy of gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=84902505818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902505818&partnerID=8YFLogxK

U2 - 10.1016/j.clinre.2013.11.009

DO - 10.1016/j.clinre.2013.11.009

M3 - Article

C2 - 24485596

AN - SCOPUS:84902505818

VL - 38

SP - 372

EP - 378

JO - Clinics and Research in Hepatology and Gastroenterology

JF - Clinics and Research in Hepatology and Gastroenterology

SN - 2210-7401

IS - 3

ER -